<SEC-DOCUMENT>0001193805-25-000454.txt : 20250409
<SEC-HEADER>0001193805-25-000454.hdr.sgml : 20250409
<ACCEPTANCE-DATETIME>20250409172607
ACCESSION NUMBER:		0001193805-25-000454
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20250409
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250409
DATE AS OF CHANGE:		20250409

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		25825989

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e664373_8k-immunic.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:IMUX="http://imux.com/20250409">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_IMUX_imux.com_20250409 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250409_20250409 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001280776 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000004" name="dei:EntityCentralIndexKey">0001280776</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="imux-20250409.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-04-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-09</xbrli:startDate>
        <xbrli:endDate>2025-04-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_907_edei--DocumentType_c20250409__20250409_zn218iXQ2vea"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT<br/>
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):&#160;<span id="xdx_904_edei--DocumentPeriodEndDate_c20250409__20250409_zBnHijI2i6sg"><ix:nonNumeric contextRef="AsOf2025-04-09" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">April
9, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityRegistrantName_c20250409__20250409_z9JSTFASiFcl"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000011" name="dei:EntityRegistrantName">IMMUNIC, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20250409__20250409_zae7V0nUHVk8"><ix:nonNumeric contextRef="AsOf2025-04-09" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityFileNumber_c20250409__20250409_z50ZGfXz3VEa"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000013" name="dei:EntityFileNumber">001-36201</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20250409__20250409_zrl6534Le1vb"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000014" name="dei:EntityTaxIdentificationNumber">56-2358443</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>(State or other jurisdiction<br/>
of incorporation)</b></span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(Commission File Number)</b></span></td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(IRS Employer Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20250409__20250409_z7YF2ToFwIA1"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000015" name="dei:EntityAddressAddressLine1">1200 Avenue of the Americas</ix:nonNumeric></span>,<span id="xdx_909_edei--EntityAddressAddressLine2_c20250409__20250409_zONgAYIry4g3"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000016" name="dei:EntityAddressAddressLine2">&#160;Suite 200</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20250409__20250409_zQJfDAQoyUu8"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000017" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>,&#160;<span id="xdx_903_edei--EntityAddressStateOrProvince_c20250409__20250409_zmegak3Q1mKf"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000018" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span>&#160;<span id="xdx_901_edei--EntityAddressPostalZipCode_c20250409__20250409_zaS1fRjSNcac"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000019" name="dei:EntityAddressPostalZipCode">10036</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCountry_c20250409__20250409_zPwFzVGyOjn2"><ix:nonNumeric contextRef="AsOf2025-04-09" format="ixt-sec:countrynameen" id="Fact000020" name="dei:EntityAddressCountry">USA</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code:&#160;<span id="xdx_908_edei--CityAreaCode_c20250409__20250409_zAJfXuW8aZv6"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000021" name="dei:CityAreaCode">(332)</ix:nonNumeric></span>&#160;<span id="xdx_902_edei--LocalPhoneNumber_c20250409__20250409_zvoQAmxcKVg8"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000022" name="dei:LocalPhoneNumber">255-9818</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--WrittenCommunications_c20250409__20250409_zpxaeF2Vt4x8"><ix:nonNumeric contextRef="AsOf2025-04-09" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 95%"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SolicitingMaterial_c20250409__20250409_zBpobvLwXidb"><ix:nonNumeric contextRef="AsOf2025-04-09" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20250409__20250409_z0wBwLqVQik6"><ix:nonNumeric contextRef="AsOf2025-04-09" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20250409__20250409_zoERjnpowcFg"><ix:nonNumeric contextRef="AsOf2025-04-09" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 36%; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 21%; text-align: center"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 43%; text-align: center"><span style="font-size: 10pt">Name of exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20250409__20250409_z1M6RYFOsnBe"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000027" name="dei:Security12bTitle">Common Stock, par value $0.0001</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20250409__20250409_zwUKjf6Zkch7"><ix:nonNumeric contextRef="AsOf2025-04-09" id="Fact000028" name="dei:TradingSymbol">IMUX</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">The <span id="xdx_901_edei--SecurityExchangeName_c20250409__20250409_zQe3yF5ItLIl"><ix:nonNumeric contextRef="AsOf2025-04-09" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167; 240.12b2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20250409__20250409_zRVrTGuvcyJ4"><ix:nonNumeric contextRef="AsOf2025-04-09" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. Yes&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;No&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 100%"><span style="font-size: 10pt"><b>Item 1.01. Entry Into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 9, 2025, Immunic, Inc. (the &#8220;Company&#8221;) entered
into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with certain institutional and accredited investors
(the &#8220;Investors&#8221;) relating to the issuance and sale of an aggregate of 5,666,667 shares (the &#8220;Shares&#8221;) of the
Company&#8217;s common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;). The purchase price per Share was $0.90 for aggregate
gross proceeds to the Company of approximately $5.1 million. The offer and sale of the Shares is referred to herein as the &#8220;Offering.&#8221;
The Offering is expected to close on April 10, 2025, subject to customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, on April 9, 2025, the Company entered into a placement
agency agreement (the &#8220;Placement Agency Agreement&#8221;) with Titan Partners Group LLC, a division of American Capital Partners,
LLC (the &#8220;Placement Agent&#8221;), relating to the Offering. Pursuant to the Placement Agency Agreement, the Company agreed to pay
the Placement Agent a cash fee of 6.0% of the gross proceeds from the Offering raised from Investors and to reimburse the Placement Agent
for certain costs incurred in connection therewith. Additionally, upon the closing of the Offering, the Company agreed to issue to the
Placement Agent, or its designees, warrants to purchase up to an aggregate of 283,334 shares of Common Stock, representing 5.0% of the
Shares sold in the Offering (the &#8220;Placement Agent Warrants&#8221;). The Placement Agent Warrants will be exercisable, in whole or
in part, commencing 180 days from the date of the Placement Agency Agreement and expiring on the five year anniversary of the Placement
Agency Agreement, at an initial exercise price per share of Common Stock of $1.125, which is equal to 125% of the price per Share to Investors
in the Offering.&#160; The Placement Agent Warrants and the shares of Common Stock underlying the Placement Agent Warrants were offered
pursuant to the exemptions from registration provided in Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The net proceeds to the Company from the Offering, after deducting
commissions and the Company&#8217;s estimated offering expenses, are expected to be approximately $4.6 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Shares registered under the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), on the Company&#8217;s Registration Statement on Form S-3 (Registration No. 333-275717), previously
filed with the Securities and Exchange Commission and declared effective on May 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The representations, warranties and covenants contained in the Securities
Purchase Agreement were made solely for the benefit of the parties to the Securities Purchase Agreement. In addition, such representations,
warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Securities Purchase Agreement and
not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material
by stockholders of, or other investors in, the Company. Accordingly, the Securities Purchase Agreement is included with this filing only
to provide investors with information regarding the terms of the transactions. Moreover, information concerning the subject matter of
the representations and warranties may change after the date of the Securities Purchase Agreement, which subsequent information may or
may not be fully reflected in public disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Placement Agent Warrants, Placement
Agency Agreement and the Securities Purchase Agreement are subject to, and qualified in their entirety by, the forms of Placement Agent
Warrant, Placement Agency Agreement and Securities Purchase Agreement attached hereto as Exhibits 4.1, 10.1 and 10.2, respectively, and
incorporated herein by reference. Dentons US LLP, counsel to the Company, delivered an opinion as to legality of the issuance of the Shares
in the Offering, a copy of which is attached hereto as Exhibit 5.1 and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 46%"><span style="font-size: 10pt"><b>Item 3.02. Unregistered Sales of Equity Securities</b></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information above related to the issuance of the Placement Agent
Warrants is incorporated by reference into this Item 3.02.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 46%"><span style="font-size: 10pt"><b>Item 7.01. Regulation FD Disclosure </b></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 9, 2025, the Company issued a press release with respect to
the information set forth above. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The
disclosure in this Item 7.01 (including the exhibit) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of Section 18, nor shall it be deemed incorporated
by reference in any of the Company&#8217;s filings under the Securities Act or the Exchange Act, except to the extent, if any, expressly
set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 46%"><span style="font-size: 10pt"><b>Item 9.01. Financial Statements and Exhibits.</b></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Exhibits. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: white 1pt solid; text-align: center; white-space: nowrap; width: 12%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Exhibit</b></p>
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>No. </b></p></td>
    <td style="border-bottom: white 1pt solid; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664373_ex4-1.htm">Form of Placement Agent Warrant</a> </span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">5.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664373_ex5-1.htm">Opinion of Dentons US LLP</a></span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664373_ex10-1.htm">Form of Placement Agency Agreement</a></span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">10.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664373_ex10-2.htm">Form of Securities Purchase Agreement</a></span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">23.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664373_ex5-1.htm">Consent of Dentons US LLP (contained in Exhibit 5.1)</a></span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">99.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt"><a href="e664373_ex99-1.htm">Press Release</a></span></td></tr>
  <tr style="background-color: white">
    <td style="text-align: center; white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Cover Page to this Current Report on Form 8-K in Inline XBRL</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Dated: April 9, 2025</span></td>
    <td colspan="2"><span style="font-size: 10pt"><b>Immunic, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 35%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Daniel Vitt</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Daniel Vitt</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LbMrKrJLhw5xigwRb6uLUtyakda/R/ItrRtiCITknC9HiIHIaWFqZDjMygJ22LS19gglnpHRnjA4suUqhTBLvBjnWVvfrT8wo8BgYCaxPIZ757wbh1UKcjSU06EaQ5KkSsF2LaKvnpE9mwqtN7oGbSvYMrVs0Gt+9R92+kmWmleXtEd2hmwKSSx7+Q1KJgo2dNcP4quDoshENOgqEjnTrQ2u+dOj/ZIwr7EJca6n/x19AMmRSlk= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>e664373_ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO
THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE
144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER
LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>IMMUNIC,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Warrant Shares: 283,334</P></TD>
  <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Initial Exercise Date: October 9, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Issue Date: April 10, 2025</P>
</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;)
certifies that, for value received, American Capital Partners, LLC or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon
the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date referred
to above as the Initial Exercise Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time)
on April 9, 2030 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Immunic Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), up to 283,334 shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><U>Section 1</U>.&nbsp;<U>Definitions</U>. Capitalized terms used and
not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;),
dated April 9, 2025, between the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;<U>Exercise of Warrant</U>. Subject to the provisions of Section 2(e) herein, exercise of the purchase rights represented by this
Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination
Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the
form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number of
Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified
in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. The Company may reasonably rely on the authenticity of the information
provided by the Holder in the Notice of Exercise and shall have no obligation to inquire with respect to or otherwise confirm the authenticity
of the signature(s) contained on any Notice of Exercise nor the authority of the person so executing such Notice of Exercise. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day
of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) &nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $<B>1.125</B>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,</FONT>&nbsp;&nbsp;<U>Cashless Exercise</U>. In lieu of exercising this Warrant by delivering the aggregate Exercise Price by wire transfer or cashier&rsquo;s
check, at the election of Holder, this Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 75pt"></TD><TD STYLE="width: 20.25pt">(A)</TD><TD STYLE="text-align: justify">= as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading
Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)
at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the
date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof
after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>(B)</TD><TD STYLE="text-align: justify">= the Exercise
Price of this Warrant, as adjusted hereunder; and</TD></TR>
                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>(X)</TD><TD STYLE="text-align: justify">= the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</TD></TR>
                                                                                     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 75pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock are then listed
or quoted on The New York Stock Exchange, the NYSE American or any tier of The Nasdaq Stock Market (each, a &ldquo;Trading Market&rdquo;),
the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which
the Common Stock are then listed or quoted as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) (based on a trading day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock are listed or quoted on the OTCQB or OTCQX (each as operated
by OTC Markets Group, Inc., or any successor market), the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock are not then listed or quoted for trading on the OTCQB or OTCQX
Markets and if prices for the Common Stock are then reported in the OTC Pink Market published by OTC Markets Group Inc. (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a Common Stock as determined by an independent appraiser selected in good faith by
the Board of Directors of the Company and reasonably acceptable to the Holder, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in
good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position
contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 9pt">i.</TD><TD STYLE="text-align: justify"><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased
hereunder to be transmitted by the Company&rsquo;s transfer agent (the &ldquo;<U>Transfer Agent</U>&rdquo;) to the Holder by crediting
the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Transfer Agent is then a participant in such system and either (A) there is an
effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) the
Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise
by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for
the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice
of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company by the Holder of the Notice of
Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice
of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall
be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has
been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other
than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days
comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver
to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder,
in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of
the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth
Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant
Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST
program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means
the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the
Common Stock as in effect on the date of delivery of the Notice of Exercise.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.&#8239;&#8239;<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; provided, however,
that the Holder shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently
with the return to the Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of the Holder&rsquo;s
right to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing such
restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.&#8239;&#8239;<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.&#8239;&#8239;<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.&#8239;&#8239;<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.&#8239;&#8239;<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">e)&#8239;&#8239;<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have
the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall not have any liability for
any error made by the Holder or any other Person. In addition, a determination as to any group status as contemplated above shall be determined
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section
2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common
Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)
a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth
the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior
to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the
Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><U>Section 3</U>.&#9;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification. For the purposes of clarification, the Exercise Price
of this Warrant will not be adjusted in the event that the Company or any subsidiary thereof, as applicable, sells or grants any option
to purchase, or sell or any grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option
to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the Exercise
Price then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time while this Warrant
is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other
property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,
that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution (other than cash) of stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than for the purpose
of changing the Company&rsquo;s name and/or the jurisdiction of incorporation of the Company or a holding company of the Company), (ii)
the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock or 50% or more of the voting power of the then outstanding common equity of the Company, (iv) the Company,
directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the then outstanding
shares of Common Stock or 50% or more of the voting power of the then outstanding common equity of the Company (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction (without regard
to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt">The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d)
pursuant to written agreements in form and substance reasonably satisfactory to the Company prior to such Fundamental Transaction and
shall deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&#8239;&#8239;<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&#8239;&#8239;<U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&#8239;&#8239;<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&#8239;&#8239;<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice and provided further that no notice shall be required if the information is in a press release disseminated
by the Company or document filed by the Company with the Commission. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file
such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;<U>Transferability</U>. Pursuant to FINRA Rule 5110(e)(1), neither this Warrant nor any Warrant Shares issued upon exercise of
this Warrant shall be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative,
put or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days
immediately following the commencement of sales of the offering pursuant to which this Warrant is being issued, except as permitted under
FINRA Rule 5110(e)(2). Subject to the foregoing restriction, this Warrant and all rights hereunder are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;<U>Representation by Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act. Notwithstanding the foregoing, the Holder may transfer
all or any portion of this Warrant in transactions which are exempt from registration pursuant to Section 4(a)(7) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&#9;[<U>Reserved]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 6</U>.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;<U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&#8239;&#8239;<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,
shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City
of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of
New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&#8239;&#8239;<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&#8239;&#8239;<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other
provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&#8239;&#8239;<U>Notices</U>. Any and all notices or other communications or deliveries to be provided hereunder shall be made pursuant to the
certain placement agency agreement dated on or about the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&#8239;&#8239;<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)&#8239;&#8239;<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)&#8239;&#8239;<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)&#8239;&#8239;<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and the Holder, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)&#8239;&#8239;<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&#8239;&#8239;<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>IMMUNIC, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Name:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;IMMUNIC,
INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%">Name of Investing Entity:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%"><I>Signature of Authorized Signatory of Investing
Entity</I>:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%">Name of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%">Title of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%">Date:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: justify; font-size: 10pt"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="text-decoration: none double"></FONT>Phone
    Number:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: justify; font-size: 10pt"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="text-decoration: none double"></FONT>Email
    Address: </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 6%">Dated:</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 45%"> ________________ ___, ________</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt; width: 20%">Holder&rsquo;s Signature:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 30%"> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"></TD></TR>
</TABLE>
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt; width: 20%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Holder&rsquo;s Address:</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 30%"> </TD>
    <TD STYLE="text-align: justify; font-size: 10pt"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>e664373_ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="2" STYLE="width: 30%; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 41px; width: 160px"></TD>
    <TD STYLE="width: 35%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 35%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 7pt">Dentons US LLP</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 7pt">1221 Avenue of
    the Americas<BR>
    New York, NY 10020-1089 USA<BR>
    United States<BR>
    <BR>
    T +1 212 768 6700</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 7pt">F +1 212 768 6800</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 7pt">dentons.com</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 9, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immunic, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1200 Avenue of the Americas, Suite 200</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10036</P></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">Re:</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt"><U>Immunic, Inc. &ndash; Registration Statement on Form S-3</U></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">In our capacity as special
counsel to Immunic, Inc., a corporation organized under the laws of the State of Delaware (the &ldquo;<U>Company</U>&rdquo;), we have
been asked to render this opinion in connection with a registration statement on Form S-3 (File No. 333-275717) (the &ldquo;<U>Registration
Statement</U>&rdquo;), which Registration Statement the Company initially filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;) on November 22, 2023, and which the Commission
declared effective on May 31, 2024, and the prospectus supplement filed pursuant to Rule 424(b) under the Securities Act, dated April
9, 2025 (the &ldquo;<U>Prospectus Supplement</U>&rdquo;), under which the Company is offering up to 5,666,667 shares of the Company&rsquo;s
common stock, $0.0001 par value per share (the &ldquo;<U>Shares</U>&rdquo;). The Shares are being sold pursuant to a securities purchase
agreement dated as of April 9, 2025, by and between the Company and each purchaser party thereto (the &ldquo;<U>Purchase Agreement</U>&rdquo;).
Capitalized terms used but not otherwise defined herein shall have the meanings assigned to such terms in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are delivering this opinion
to you at your request in accordance with the requirements of Item 16 of Form S-3 and Item 601(b)(5) of Regulation S-K under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with rendering
this opinion, we have examined originals, certified copies or copies otherwise identified as being true copies of the following: (i) the
Company&rsquo;s Certificate of Incorporation, as amended and restated, (ii) the Company&rsquo;s bylaws, as amended and restated (iii)
the Registration Statement, including the prospectus (the &ldquo;<U>Base Prospectus</U>&rdquo;) contained therein, (iv) the Prospectus
Supplement (the Prospectus Supplement and the Base Prospectus are collectively referred to herein as the &ldquo;<U>Prospectus</U>&rdquo;),
(v) corporate proceedings of the Company relating to the Shares, and (vi) such other instruments and documents as we have deemed relevant
under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In making the aforesaid examinations,
we have assumed the genuineness and authenticity of all documents examined by us and all signatures thereon, and the conformity to originals
of all copies of all documents examined by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing, and
in reliance thereon, and subject to the qualifications, limitations and exceptions stated herein, we are of the opinion that the Shares
have been duly authorized and, when issued and delivered by the Company against due payment therefor in accordance with the terms set
forth in the Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<P STYLE="text-indent: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">The foregoing opinion is limited to the laws of the State of Delaware
(excluding local laws) and the federal law of the United States of America. No opinion is expressed herein with respect to the qualification
of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the
use of our opinion as Exhibit 5.1 to the Registration Statement and to the reference to this firm and this opinion under the heading
&ldquo;Legal Matters&rdquo; in the Prospectus comprising a part of the Registration Statement and any amendment thereto. In giving such
consent, we do not hereby admit that we come within the category of persons whose consent is required under Section 7 of the Act, or
the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="width: 6%">&nbsp;</TD>
  <TD STYLE="width: 35%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>/s/ Dentons US LLP</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>e664373_ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENCY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">April 9, 2025&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Titan Partners Group LLC,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a division of American Capital Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4 World Trade Center, 29th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10007</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Introductory</B>. This
Placement Agency Agreement the (&ldquo;<B>Agreement</B>&rdquo;) sets forth the terms upon which Titan Partners Group LLC, a division of
American Capital Partners, LLC (&ldquo;<B>Titan Partners</B>&rdquo; or the &ldquo;<B>Placement Agent</B>&rdquo;), shall be engaged by
Immunic, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), to act as the exclusive Placement Agent in connection with the
registered direct offering (hereinafter referred to as the &ldquo;<B>Placement</B>&rdquo;) of shares of common stock, par value $0.0001
per share (the &ldquo;<B>Common Stock</B>&rdquo; and the Common Stock offered in the Placement, the &ldquo;<B>Placement Securities</B>&rdquo;),
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Placement
and the Placement Securities shall be mutually agreed upon by the Company and the purchasers (each, a &ldquo;<B>Purchaser</B>&rdquo; and
collectively, the &ldquo;<B>Purchasers</B>&rdquo;) and nothing herein constitutes that the Placement Agent would have the power or authority
to bind the Company or any Purchaser or an obligation for the Company to issue any Placement Securities or complete the Placement. The
date of the closing of the Placement shall be referred to herein as the &ldquo;<B>Closing Date</B>&rdquo;. The Company expressly acknowledges
and agrees that the Placement Agent&rsquo;s obligations hereunder are on a reasonable best efforts basis only and that the execution of
this Agreement does not constitute a commitment by the Placement Agent to purchase the Placement Securities and does not ensure the successful
placement of the Placement Securities or any portion thereof or the success of the Placement Agent with respect to securing any other
financing on behalf of the Company. Following the prior written consent of the Company, the Placement Agent may retain other brokers or
dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement. The sale of the Placement Securities
to any Purchaser will be evidenced by the securities purchase agreement (the &ldquo;<B>Purchase Agreement</B>&rdquo;) by and among the
Company and such Purchasers in the form of <U>Exhibit A</U> attached hereto. Capitalized terms that are not otherwise defined herein have
the meanings given to such terms in the Purchase Agreement. Prior to the signing of any Purchase Agreement, executive officers of the
Company will be available upon reasonable notice and during normal business hours to answer inquiries from prospective Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 1</U>. <U>REPRESENTATIONS
AND WARRANTIES OF THE COMPANY; COVENANTS OF THE COMPANY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. <U>Representations of the
Company</U>. With respect to the Placement Securities, each of the representations and warranties (together with any related disclosure
schedules thereto) and covenants made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement, is
hereby incorporated herein by reference into this Agreement (as though fully restated herein) and is, as of the date of this Agreement
and as of each Closing Date, hereby made to, and in favor of, the Placement Agent. In addition to the foregoing, the Company represents
and warrants that there are no affiliations with any FINRA member firm participating in the Placement among the Company&rsquo;s officers,
directors or, to the knowledge of the Company, any five percent (5.0%) or greater stockholder of the Company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. <U>Covenants of the Company</U>.
The Company covenants and agrees to continue to retain (i) a firm of independent PCAOB registered public accountants for a period of at
least five (5) years after the Initial Closing Date and (ii) a competent transfer agent with respect to the Common Stock for a period
of five (5) years after the Initial Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 2</U>. <U>REPRESENTATIONS
OF THE PLACEMENT AGENT</U>. The Placement Agent represents and warrants that it (i) is a member in good standing of the Financial Industry
Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;), (ii) is registered as a broker/dealer under the Securities Exchange Act of 1934, as
amended (the &ldquo;<B>Exchange Act</B>&rdquo;), (iii) is licensed as a broker/dealer under the laws of the United States of America,
applicable to the offers and sales of the Placement Securities by the Placement Agent, (iv) is and will be a corporate body validly existing
under the laws of its place of incorporation, and (v) has full power and authority to enter into and perform its obligations under this
Agreement. The Placement Agent will immediately notify the Company in writing of any change in its status with respect to subsections
(i) through (v) above. The Placement Agent covenants that it will use its reasonable best efforts to conduct the Placement hereunder in
compliance with the provisions of this Agreement and the requirements of applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 3</U>. <U>COMPENSATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;<P STYLE="text-indent: 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt">A.&nbsp;<U>Cash Compensation</U>. In consideration of the services
to be provided for hereunder, the Company shall pay to the Placement Agent or its respective designees a total cash fee equal to six percent
(6.0%) of the gross proceeds from the Placement of the total amount of Placement Securities sold (collectively, the &ldquo;<B>Cash Fee</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. <U>Warrant Compensation</U>.
In consideration of the services to be provided for hereunder, the Company shall pay to the Placement Agent or its respective designees
at the Initial Closing Date and each Additional Closing Date, if any, warrants (&ldquo;<B>Agent Warrants</B>&rdquo;) for the purchase
of an aggregate of a number of shares of Common Stock (the &ldquo;<B>Agent Warrant Shares</B>&rdquo;), representing 5.0% of the Placement
Securities sold at such Closing Date. The Agent Warrants, in the form of <U>Exhibit B</U> hereto, shall be exercisable, in whole or in
part, commencing on the date that is 180 days after the date of this Agreement and expiring on the five-year anniversary of the date of
this Agreement at an initial exercise price per share of Common Stock of $1.125. The Placement Agent understands and agrees that there
are significant restrictions pursuant to FINRA Rule 5110 against transferring the Agent Warrants and the Agent Warrant Shares during the
one hundred eighty (180) days after this Agreement and by its acceptance thereof shall agree that it will not sell, transfer, assign,
pledge or hypothecate the Agent Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call
transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following
the date of this Agreement to anyone other than (i) a sub-agent or selected-dealer in connection with the Placement or (ii) a bona fide
officer, partner, employee or registered representative of the Placement Agent, sub-agent or selected-dealer; and only if any such transferee
agrees to the foregoing lock-up restrictions. Delivery of the Agent Warrants shall be made at the relevant Closing Date, and shall be
issued in the name or names and in such authorized denominations as the Placement Agent may request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. <U>Advance</U>. Prior to
the execution of this Agreement, the Company shall have paid to the Placement Agent an advance in the amount of $15,000 to be credited
against the accountable expenses actually incurred by the Placement Agent that may be reimbursed pursuant to Section 4. Such advance shall
have been made in accordance with FINRA Rule 5110(g)(4)(A).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E. <U>Reduction of Compensation</U>.
The Placement Agent reserves the right to reduce any item of compensation or adjust the terms thereof as specified herein in the event
that a determination shall be made by FINRA to the effect that the Placement Agent&rsquo;s aggregate compensation is in excess of FINRA
Rules or that the terms thereof require adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">F. <U>Fee Tail</U>. Subject
to the terms and exceptions provided for in that certain Financing Engagement Agreement, dated as of March 19, 2025, as amended, by and
between the Placement Agent and the Company (the &ldquo;<B>Engagement Agreement</B>&rdquo;), the Placement Agent shall be entitled to
the compensation calculated in the manner set forth herein with respect to any public or private offering or other financing or capital-raising
transaction of any kind (the &ldquo;<B>Tail Financing</B>&rdquo;) to the extent that such financing or capital is provided to the Company
(and actually received by the Company) by investors not already known to the Company and whom the Placement Agent contacted during the
Term (as defined in the Engagement Agreement), if such Tail Financing is consummated at any time prior to the six month anniversary following
the later of (i) the closing of the Placement hereby and (ii) the expiration or termination of the Engagement Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 4. EXPENSES</U>.
The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in
connection with the transactions contemplated hereby, including, without limitation: (i) all expenses incident to the issuance, delivery
and qualification of the Placement Securities (including all printing and engraving costs); (ii) all fees and expenses of the registrar
and transfer agent for the Common Stock ; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and
sale of the Placement Securities; (iv) all fees and expenses of the Company&rsquo;s counsel, independent public or certified public accountants
and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution
of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), and the Prospectus,
and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, reasonable attorneys&rsquo; fees and expenses incurred
by the Company in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or
any part of the Placement Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other
country; (vii) the fees and expenses associated with including the Placement Securities on the Trading Market; (viii) up to $75,000 for
the fees and expenses of the Placement Agent, including the fees and expenses of Ellenoff Grossman &amp; Schole LLP, counsel to the Placement
Agent. The Placement Agent may deduct from the net proceeds of the Offering payable to the Company on each Closing Date, the expenses
set forth herein to be paid by the Company to the Placement Agent, to the extent not already paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 5</U>. <U>INDEMNIFICATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. To the extent permitted by
law, with respect to the Placement Securities, the Company will indemnify the Placement Agent and its affiliates, stockholders, directors,
officers, employees, members and controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act) against all losses, claims, damages, expenses and liabilities, as the same are incurred (including the reasonable fees and expenses
of counsel), relating to or arising out of its activities hereunder or pursuant to this Agreement or the Purchase Agreement, including,
without limitation, any failure by the Company to obtain any required consent, except to the extent that any losses, claims, damages,
expenses or liabilities (or actions in respect thereof) are found in a final judgment (not subject to appeal) by a court of law to have
resulted primarily and directly from a Placement Agent&rsquo;s willful misconduct or gross negligence in performing the services described
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. Promptly after receipt by
the Placement Agent of notice of any claim or the commencement of any action or proceeding with respect to which the Placement Agent is
entitled to indemnity hereunder, the Placement Agent will promptly notify the Company in writing of such claim or of the commencement
of such action or proceeding, but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder,
except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company
so elects or is requested by the Placement Agent, the Company will assume the defense of such action or proceeding and will employ counsel
reasonably satisfactory to the Placement Agent and will pay the fees and expenses of such counsel. Notwithstanding the preceding sentence,
the Placement Agent will be entitled to employ its own counsel separate from counsel for the Company and from any other party in such
action if counsel for the Placement Agent reasonably determines that it would be inappropriate under the applicable rules of professional
responsibility for the same counsel to represent both the Company and the Placement Agent. In such event, the reasonable fees and disbursements
of no more than one such separate counsel will be paid by the Company, in addition to fees of local counsel. The Company will have the
right to settle the claim or proceeding, provided that the Company will not settle any such claim, action or proceeding without the prior
written consent of the Placement Agent, which will not be unreasonably withheld.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. The Company agrees to notify
the Placement Agent promptly of the assertion against it or any other person of any claim or the commencement of any action or proceeding
relating to a transaction contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D. If for any reason the foregoing
indemnity is unavailable to the Placement Agent or insufficient to hold the Placement Agent harmless, then the Company shall contribute
to the amount paid or payable by the Placement Agent as a result of such losses, claims, damages or liabilities in such proportion as
is appropriate to reflect not only the relative benefits received by the Company on the one hand and the Placement Agent on the other,
but also the relative fault of the Company on the one hand and the Placement Agent on the other that resulted in such losses, claims,
damages or liabilities, as well as any relevant equitable considerations. The amounts paid or payable by a party in respect of losses,
claims, damages and liabilities referred to above shall be deemed to include any legal or other fees and expenses incurred in defending
any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, the Placement Agent&rsquo;s share of the liability
hereunder shall not be in excess of the amount of fees actually received, or to be received, by the Placement Agent under this Agreement
(excluding any amounts received as reimbursement of expenses incurred by the Placement Agent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E. These indemnification provisions
shall remain in full force and effect whether or not the transaction contemplated by this Agreement is completed and shall survive the
termination of this Agreement, and shall be in addition to any liability that the Company might otherwise have to any indemnified party
under this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">F. The Placement Agent agrees
to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person,
if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any
and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a) of this section, as incurred,
but solely with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement
(or any amendment thereto), including any information deemed to be a part thereof, in reliance upon and in conformity with information
provided to the Company by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 6</U>. <U>ENGAGEMENT
TERM</U>. The Placement Agent&rsquo;s engagement hereunder will be until the later of (i) April 11, 2025 and (ii) the final Closing Date
under the Purchase Agreement. The date of termination of this Agreement is referred to herein as the &ldquo;<B>Termination Date</B>.&rdquo;
In the event, however, in the course of the Placement Agent&rsquo;s performance of due diligence it deems, it necessary to terminate the
engagement, the Placement Agent may do so prior to the Termination Date. The Company may elect to terminate the engagement hereunder for
any reason prior to the Termination Date but will remain responsible for fees pursuant to Section 3 hereof with respect to the Placement
Securities if sold in the Placement. Notwithstanding anything to the contrary contained herein, the provisions concerning the Company&rsquo;s
obligation to pay any fees actually earned pursuant to Section 3 hereof and the provisions concerning confidentiality, indemnification
and contribution contained herein will survive any expiration or termination of this Agreement. If this Agreement is terminated prior
to the completion of the Placement, all fees due to the Placement Agent as set forth in Section 3 shall be paid by the Company to the
Placement Agent on or before the Termination Date (in the event such fees are earned or owed as of the Termination Date). The Placement
Agent agrees not to use any confidential information concerning the Company provided to the Placement Agent by the Company for any purposes
other than those contemplated under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 7</U>. <U>PLACEMENT
AGENT INFORMATION</U>. The Company agrees that any information or advice rendered by the Placement Agent in connection with this engagement
is for the confidential use of the Company only in its evaluation of the Placement and, except as otherwise required by law, the Company
will not disclose or otherwise refer to the advice or information in any manner without the Placement Agent&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 8</U>. <U>NO FIDUCIARY
RELATIONSHIP</U>. This Agreement does not create, and shall not be construed as creating rights enforceable by any person or entity not
a party hereto, except those entitled hereto by virtue of the indemnification provisions hereof. The Company acknowledges and agrees that
the Placement Agent is not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity
holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of the Placement Agent hereunder,
all of which are hereby expressly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 9</U>. <U>CLOSING</U>.
The obligations of the Placement Agent, and the closing of the sale of the Placement Securities hereunder are subject to the accuracy,
when made and on the Closing Date, of the representations and warranties on the part of the Company contained herein and in the Purchase
Agreement, to the performance by the Company of its obligations hereunder, and to each of the following additional terms and conditions,
except as otherwise disclosed to and acknowledged and waived by the Placement Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. All corporate proceedings
and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement, the Placement
Securities, and all other legal matters relating to this Agreement and the transactions contemplated hereby with respect to the Placement
Securities shall be reasonably satisfactory in all material respects to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. The Placement Agent shall
have received the following on each Closing Date: (i) the favorable opinion of Dentons US LLP and Dentons Europe LLP, counsel to the Company,
and a written statement providing certain &ldquo;10b-5&rdquo; negative assurances, dated such Closing Date and addressed to the Placement
Agent, in form and substance reasonably satisfactory to the Placement Agent and (ii) Boehmert &amp; Boehmert<FONT STYLE="background-color: white">,
special counsel for the Company with respect to intellectual property matters</FONT>, dated such Closing Date and addressed to the Placement
Agent, in form and substance reasonably satisfactory to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. The Placement Agent shall
have received (i) a customary Officers&rsquo; Certificate, executed and delivered by the Company&rsquo;s executive officers, as to the
accuracy of the representations and warranties contained in the Purchase Agreement, (ii) a Chief Financial Officer&rsquo;s Certificate
regarding certain financial information included in the Registration Statement, Prospectus and Prospectus Supplement and (iii) a Secretary&rsquo;s
Certificate executed and delivered by the Company&rsquo;s corporate secretary certifying that (A) the Company&rsquo;s charter documents
are true and complete, have not been modified and are in full force and effect; (B) that the resolutions of the Company&rsquo;s Board
of Directors relating to the Placement are in full force and effect and have not been modified; (C) as to the incumbency of the officers
of the Company and (D) other customary certifications reasonably satisfactory to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E. The Placement Agent shall
have received an executed FINRA questionnaire from each of the Company and the Company&rsquo;s executive officers, directors and 5% or
greater securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">F. [Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">G. The Placement Agent shall
have received on each Closing Date satisfactory evidence of the good standing of the Company and its subsidiaries in their respective
jurisdictions of organization and their good standing as foreign corporations in such other jurisdictions as the Placement Agent may reasonably
request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions,
dated no more than one (1) business day prior to such Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">H. The Placement Securities
shall be registered under the Exchange Act. The Company shall have taken no action designed to, or likely to have the effect of terminating
the registration of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading
Market or other applicable U.S. national exchange, nor has the Company received any information suggesting that the Commission or the
Trading Market or other U.S. applicable national exchange is contemplating terminating such registration or listing. In addition, the
Company shall have submitted a listing of additional shares notification form to the Trading Market with respect to the Placement Securities
and shall have received no objection thereto from the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">I. No action shall have been
taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would,
as of the Initial Closing Date, prevent the issuance or sale of the Placement Securities or materially and adversely affect or potentially
and adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other nature by any
federal or state court of competent jurisdiction shall have been issued as of the Initial Closing Date which would prevent the issuance
or sale of the Placement Securities or materially and adversely affect or potentially and adversely affect the business or operations
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">J. The Company shall have entered
into a Purchase Agreement with each of the Purchasers of the Placement Securities and such agreements shall be in full force and effect
and shall contain representations, warranties and covenants of the Company as agreed upon between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">K. FINRA shall have raised no
objection to the fairness and reasonableness of the terms and arrangements of this Agreement. In addition, the Company shall, if requested
by the Placement Agent, make or authorize Placement Agent&rsquo;s counsel to make on the Company&rsquo;s behalf, any filing with the FINRA
Corporate Financing Department pursuant to FINRA Rule 5110 with respect to the Placement and pay all filing fees required in connection
therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the conditions specified
in this Section 9 shall not have been fulfilled when and as required by this Agreement, all obligations of the Placement Agent hereunder
may be cancelled by the Placement Agent at, or at any time prior to, any Closing Date. Notice of such cancellation shall be given to the
Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 10</U>. <U>GOVERNING
LAW</U>. This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements
made and to be performed entirely in such State, without regard to principles of conflicts of law. This Agreement may not be assigned
by either party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of
the parties hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising
under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought
into the courts of the State of New York or into the Federal Court located in New York, New York and, by execution and delivery of this
Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid
courts. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If either
party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its attorney's fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 11</U>. <U>ENTIRE
AGREEMENT/MISCELLANEOUS</U>. This Agreement embodies the entire agreement and understanding between the parties hereto, and supersedes
all prior agreements and understandings, relating to the subject matter hereof. If any provision of this Agreement is determined to be
invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or any other provision
of this Agreement, which will remain in full force and effect. This Agreement may not be amended or otherwise modified or waived except
by an instrument in writing signed by both the Placement Agent and the Company. The representations, warranties, agreements and covenants
contained herein shall survive the Initial Closing Date of the Placement and delivery of the Placement Securities. This Agreement may
be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need
not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force
and effect as if such facsimile or .pdf signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 12</U>.<I>&nbsp;</I><U>NOTICES</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is sent to the email address
specified on the signature pages attached hereto prior to 6:30 p.m. (New York City time) on a business day, (b) the next business day
after the date of transmission, if such notice or communication is sent to the email address on the signature pages attached hereto on
a day that is not a business day or later than 6:30 p.m. (New York City time) on any business day, (c) the third business day following
the date of mailing, if sent by U.S. internationally recognized air courier service, or (d) upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION 13</U>. <U>PRESS
ANNOUNCEMENTS</U>. The Company agrees that the Placement Agent shall, on and after the Initial Closing Date, have the right to reference
the Placement and the Placement Agent&rsquo;s role in connection therewith in the Placement Agent&rsquo;s marketing materials and on
its website and to place advertisements in financial and other newspapers and journals, in each case at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please confirm that the foregoing
correctly sets forth our agreement by signing and returning to the Placement Agents the enclosed copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><B>TITAN PARTNERS GROUP LLC, A DIVISION OF AMERICAN CAPITAL PARTNERS, LLC</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Adam Sands</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Authorized Representative</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><U>Address for notice:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Titan Partners Group LLC, a division of American Capital Partners,
    LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4 World Trade Center, 29th Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10007</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Adam Sands</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: notices@titanpartnersgrp.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed to as of the date first written above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="text-transform: uppercase"></FONT><B>IMMUNIC, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address for notice</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immunic, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1200 Avenue of the Americas, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Glenn Whaley</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: glenn.whaley@imux.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Form of
Securities Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Form of
AGENT&rsquo;S PURCHASE WARRANT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>e664373_ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of April 9, 2025, between Immunic, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below),
the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&#8239;&#8239;<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Shares, in each case, have been satisfied or waived, but in no event later than the first (1<SUP>st</SUP>)
Trading Day following the date hereof (or the second (2<SUP>nd</SUP>) Trading Day following the date hereof if this Agreement is signed
on a day that is not a Trading Day or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading Day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Dentons US LLP, with offices located at 1221 Avenue of the Americas, New York, New York 10020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $0.90, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means Titan Partners Group LLC, a division of American Capital Partners, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission
and delivered by the Company to each Purchaser at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement on Form S-3 with Commission file No. 333-275717 which registers the sale
of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below such
Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States
dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock
Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed
in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means American Stock Transfer &amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing address
of PO Box 12893, Philadelphia, PA 19176-0893, and an e-mail address of help@astfinancial.com, and any successor transfer agent of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt">2.1&#8239;&#8239;<U>Closing</U>. On the Closing Date, upon the terms
and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties
hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $5,100,000.30
of Shares. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made
available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee. The Company shall deliver to each Purchaser
its respective Shares, and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing.
Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of EGS or
such other location as the parties shall mutually agree. Unless otherwise directed by the Placement Agent, settlement of the Shares shall
occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;DVP&rdquo;) (i.e., on the Closing Date, the Company shall issue the Shares registered
in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified
by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable
Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2&#8239;&#8239;<U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;this Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;a legal opinion of Company Counsel, in form and substance reasonably acceptable to the Placement Agent and the Purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;subject to the last sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;subject to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer
Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;this Agreement duly executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;such Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement
with the Company or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&#8239;&#8239;<U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless
as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have
been performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Company contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude
in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Shares at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;</FONT><U>Representations and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules
shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained
in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each
Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;<U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company
owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all
of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free
of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to
the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;<U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (if a good standing concept
exists in such jurisdiction), with the requisite power and authority to own and use its properties and assets and to carry on its business
as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective
certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries
is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the
nature of the business conducted or property owned by it makes such qualification necessary (if a good standing concept exists in such
jurisdiction), except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;); provided that
a change in the market price or trading volume of the Common Stock alone shall not be deemed, in and of itself, to constitute a Material
Adverse Effect, and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke,
limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;<U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and
the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection
herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which
it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms
hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with
its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and
other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;<U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents
to which it is a party, the issuance and sale of the Shares and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets
of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property
or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in
a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not
have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;<U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give
any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.3 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s)
to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner required thereby and (iv) such
filings as are required to be made under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;<U>Issuance of the Shares; Registration</U>. The Shares are duly authorized and, when issued and paid for in accordance with the
applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by
the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant
to this Agreement. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities
Act, which became effective on&nbsp;May 31, 2024 (the &ldquo;<U>Effective Date</U>&rdquo;), including the Prospectus, and such amendments
and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities
Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of
the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the
Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus
with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective, at the
date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all
material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus
and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing
Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an
untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration Statement
eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements with
respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior to this
offering, as set forth in General Instruction I.B.1 of Form S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;<U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which
<U>Schedule 3.1(g)</U> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the
Company as of the date hereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange
Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares
of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except for options and restricted stock units granted under the Company&rsquo;s option plans, there are
no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities,
rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire,
any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which
the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital
stock of any Subsidiary. The issuance and sale of the Shares will not obligate the Company or any Subsidiary to issue shares of Common
Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company
or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon
an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary
that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the
Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any
stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding
shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance
with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. Except for the Required Approvals, no further approval or authorization of any stockholder,
the Board of Directors or others is required for the issuance and sale of the Shares. There are no stockholders agreements, voting agreements
or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of
the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&#8239;&#8239;<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and
the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations
of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;<U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements
included within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development
that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with
past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed
in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or
made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase
or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate,
except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential
treatment of information. Except for the issuance of the Shares contemplated by this Agreement or as set forth on <U>Schedule 3.1(h)</U>,
no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist
with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial
condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&#8239;&#8239;<U>Litigation</U>. Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;).&nbsp; None of the Actions set forth on Schedule 3.1(j) (i) adversely
affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Shares or (ii) could, if there
were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.. Neither the Company nor any Subsidiary,
nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not
pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the
Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company or any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&#8239;&#8239;<U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the
Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that
their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and
foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)&#8239;&#8239;<U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under),
nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)&#8239;&#8239;<U>Environmental Laws</U>.&#9;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign
laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface
or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)&#8239;&#8239;<U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the
SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect
(&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to
the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)&#8239;&#8239;<U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned
by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which
is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)&#8239;&#8239;<U>Intellectual Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of
this Agreement, except as would not reasonably be expected to be material to the Company. Neither the Company nor any Subsidiary has received,
since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has
any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably
be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable
and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have
taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where
failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)&#8239;&#8239;<U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged,
including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither
the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant
increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)&#8239;&#8239;<U>Transactions With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors
of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)&#8239;&#8239;<U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such
disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules
and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as
of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such
term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially
affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)&#8239;&#8239;<U>Certain Fees</U>. Except as set forth in the Prospectus Supplement, no brokerage or finder&rsquo;s fees or commissions are or
will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section
that may be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)&#8239;&#8239;<U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;<U>Registration Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the
Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)&#8239;&#8239;<U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the
Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements
of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance
with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository
Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company
(or such other established clearing corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)&#8239;&#8239;<U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the
Company&rsquo;s issuance of the Shares and the Purchasers&rsquo; ownership of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)&#8239;&#8239;<U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their
agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not
otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing
representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company
to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including
the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were
made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken
as a whole with the Company&rsquo;s SEC Reports do not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they
were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or
warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)&#8239;&#8239;<U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any
offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the
Shares to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading
Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)&#8239;&#8239;<U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the
receipt by the Company of the proceeds from the sale of the Shares hereunder, (i) the fair saleable value of the Company&rsquo;s assets
exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking
into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or
circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws
of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U> sets forth as of the date hereof all outstanding secured
and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes
of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000
(other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases
required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)&#8239;&#8239;<U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for
any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)&#8239;&#8239;<U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)&#8239;&#8239;<U>Accountants</U>. The Company&rsquo;s accounting firm is Baker Tilly Virchow Krause, LLP. To the knowledge and belief of the
Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion
with respect to the financial statements included in the Company&rsquo;s Annual Report for the fiscal year ended December 31, 2024.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)&#8239;&#8239; <U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Shares</U>. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers&rsquo; purchase of the Shares. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff)&#8239;&#8239;<FONT STYLE="text-decoration: none double">Acknowledgment Regarding Purchaser&rsquo;s Trading Activity. Anything
in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f) and 4.11 hereof), it is understood and
acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to
desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo; securities based on securities
issued by the Company or to hold the </FONT>Shares <FONT STYLE="text-decoration: none double">for any specified term;
(ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo;
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of
the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which
any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv)
each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
transaction. </FONT>The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities
at various times during the period that the Shares are outstanding, and (z) such hedging activities (if any) could reduce the value of
the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted.&nbsp;
The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)&#8239;&#8239;<U>Regulation M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement agent in connection
with the placement of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)&#8239;&#8239;<U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by
the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or
any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its
Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and
which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company
have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA.&nbsp;
The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any
product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing
for marketing any product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;<U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)
in accordance with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market
value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)&#8239;&#8239;<U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)&#8239;&#8239;<U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)&#8239;&#8239;<U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)&#8239;&#8239;<U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering
Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary,
threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&#8239;&#8239;<U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents
and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which
case they shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(a)&#8239;&#8239;<U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which
it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will
constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)
as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(b)&#8239;&#8239;<U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Shares as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Shares (this representation
and warranty not limiting such Purchaser&rsquo;s right to sell the Shares pursuant to the Registration Statement or otherwise in compliance
with applicable federal and state securities laws). Such Purchaser is acquiring the Shares hereunder in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(c)&#8239;&#8239;<U>Purchaser Status</U>. At the time such Purchaser was offered the Shares, it was, and as of the date hereof it is an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(d)&#8239;&#8239;<U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Shares, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment
in the Shares and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(e)&#8239;&#8239;<U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Shares
and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that neither the
Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the
Shares nor is such information or advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate has made or makes any
representation as to the Company or the quality of the Shares and the Placement Agent and any Affiliate may have acquired non-public information
with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection with the issuance of the Shares
to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(f)&#8239;&#8239;<U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser
has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed
any purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth
the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the
foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to
the portion of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement.
Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company acknowledges and
agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on
the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or
similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&#8239;&#8239;<U>Furnishing of Information</U>. Until the one year anniversary of the Closing Date, the Company covenants to timely file (or
obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after
the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act;
provided, however that this covenant shall not prevent a sale, merger or similar transaction involving the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;</FONT><U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Shares for purposes of
the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&#8239;&#8239;<U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the
material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents
as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release,
the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of
the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection
with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company
acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between
the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand,
and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult
with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor
any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company,
with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release
of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case
the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with
the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required
by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such
disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice
of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&#8239;&#8239;<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other
Person, that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted
by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Shares under the Transaction Documents or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&#8239;&#8239;<U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, which shall be disclosed pursuant to Section 4.3, the Company covenants and agrees that neither it, nor any other
Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt
of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company
delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and
agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective
officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser
shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the
foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&#8239;&#8239;<U>Use of Proceeds</U>. Except as set forth on <U>Schedule 4.6</U> attached hereto, the Company shall use the net proceeds from
the sale of the Shares hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion
of the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in
violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&#8239;&#8239;<U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.7, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur
as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in
this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any
of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser Party&rsquo;s
representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may
have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser
Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought
against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly
notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a
material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable
to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written
consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage
or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements
made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.7
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser
Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8&#8239;&#8239;<U>Listing of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common
Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote
all of the Shares on such Trading Market and promptly secure the listing of all of the Shares on such Trading Market. The Company further
agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all
of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted on such other Trading
Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its
Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under
the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer
through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of
fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer; provided,
however that this Section 4.8 shall not prevent a sale, merger or similar transaction involving the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9&#8239;&#8239;<U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10&#8239;&#8239;<U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11&#8239;&#8239;<U>Equal Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered
or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to such Transaction Document. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the
Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase,
disposition or voting of Shares or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12&#8239;&#8239;<U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.3.<FONT STYLE="color: windowtext">&nbsp; </FONT>Each Purchaser, severally and not jointly with the other Purchasers, covenants
that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial
press release as described in Section 4.3, such Purchaser will maintain the confidentiality of the existence and terms of this transaction
and the information included in the Disclosure Schedules.&nbsp; N<FONT STYLE="color: windowtext">otwithstanding the foregoing, and notwithstanding
anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section
4.3, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance
with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.3 and (iii) no Purchaser shall have any duty of confidentiality or duty
not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described
in Section 4.3.&nbsp; </FONT>Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby
separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge
of the investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set
forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Shares covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.13&#8239;&#8239;<U>No Change of Control</U>. Each Purchaser agrees that it will not purchase Shares or acquire shares of common stock of the Company,
including currently exercisable rights to acquire such stock if that will cause such Purchaser, or any group of which such Purchaser is
a part, to have beneficial ownership of more than 19.9% of the number of outstanding shares of common stock of the Company as of the date
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&#8239;&#8239;<U>Termination</U>.&nbsp; This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder
only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other
parties, if the Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>,
<U>however</U>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&#8239;&#8239;<U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp taxes
and other taxes and duties levied in connection with the delivery of any Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&#8239;&#8239;<U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&#8239;&#8239;<U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication
is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to
be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&#8239;&#8239;<U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares
based on the initial Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived
provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group
of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of
any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the
future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay
or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or
waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable
rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment
effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Shares and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6&#8239;&#8239;<U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;</FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Shares, provided that such transferee agrees in writing to be bound, with respect to the transferred
Shares, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8&#8239;&#8239;<U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties
of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for
the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision
hereof be enforced by, any other Person, except as otherwise set forth in Section 4.7 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9&#8239;&#8239;<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations
of the Company under Section 4.7, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for
its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such
Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.10&#8239;&#8239;<U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11&#8239;&#8239;<U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature
page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12&#8239;&#8239;<U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by
such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13&#8239;&#8239;<U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14&#8239;&#8239;<U>Replacement of Shares</U>. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the
Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;</FONT><U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in
the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the
defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16&#8239;&#8239;<U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged
by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law
(including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent
of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force
and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17&#8239;&#8239;<U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction
Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in
any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any
way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this
Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company
has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because
it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in
this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18&#8239;&#8239;<U>Saturdays, Sundays, Holidays, etc.</U>&#9;If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19&#8239;<U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition,
each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20&#8239;&#8239;<B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER
PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><B>IMMUNIC, INC.</B></TD>
  <TD>&nbsp;</TD>
    <TD><U>Address for Notice:</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD>1200 Avenue of the Americas</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>&nbsp;</TD>
    <TD>Suite 200</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>&nbsp;</TD>
    <TD>New York, NY 10036</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD>Attention: Dr. Daniel Vitt</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3">With a copy to (which shall not constitute notice): </TD>
    <TD>E-mail: daniel.vitt@imux.com</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dentons US LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1221 Avenue of the Americas</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10020</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Ilan Katz</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E-mail: ilan.katz@dentons.com</P></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">IMUX
</FONT>SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%">Name of Purchaser:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%"><I>Signature of Authorized Signatory of Purchaser:</I></TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%">Name of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%">Title of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%">Email Address of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%">Facsimile Number of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; width: 5%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P></TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Shares to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: ____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>e664373_ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct
Offering, Led by Aberdeen Investments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEW YORK, April 9, 2025 /PRNewswire/ &mdash;&nbsp;Immunic, Inc.&nbsp;(&ldquo;Immunic&rdquo;
or the &ldquo;Company&rdquo;) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule
therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of a registered direct offering of 5,666,667 shares
of its common stock at the market under Nasdaq rules at a price of $0.90 per share, led by Aberdeen Investments. All securities in the
offering are being sold by Immunic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The gross proceeds from the offering are expected to be approximately
$5.1 million before deducting commissions and offering expenses. The offering is expected to close on or about April 10, 2025, subject
to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the net proceeds received
from the proposed offering to fund its clinical trials and operations and for other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Titan Partners Group, a division of American Capital
Partners, is acting as the sole placement agent for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering is being made by Immunic pursuant
to a shelf registration statement on Form S-3 (File No. 333-275717) previously filed with the Securities and Exchange Commission (the
&ldquo;SEC&rdquo;) on November 22, 2023, which became effective on May 31, 2024. The offering is being made only by means of a prospectus
supplement and the accompanying base prospectus that form a part of the registration statement. A final prospectus supplement relating
to the offering will be filed with the SEC and will be available on the SEC&rsquo;s website at <U>www.sec.gov.</U> Copies of the final
prospectus supplement and the accompanying base prospectus relating to the offering, when available, may be obtained by contacting Titan
Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, by phone at (929)
833-1246 or by email at <U>prospectus@titanpartnersgrp.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Immunic, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immunic, Inc. (Nasdaq: IMUX) is a biotechnology
company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment
of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients
suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus
calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with
additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856,
which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which
could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease,
Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being
developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Note Regarding Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy,
future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing,
development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of
such statements include, but are not limited to, statements relating to the expected timing of and funding to the company from the registered
direct offering; Immunic&rsquo;s development programs and the targeted diseases; the potential for Immunic&rsquo;s development programs
to safely and effectively target diseases; interpretation of preclinical and clinical data for Immunic&rsquo;s development programs and
potential effects; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus
of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company;
and the company&rsquo;s expected cash runway. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations
or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements.
Such statements are based on management&rsquo;s current expectations and involve substantial risks and uncertainties. Actual results
and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including,
without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine &ndash; Russia conflict and the conflict
in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash
utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and
other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and
clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company&rsquo;s
products or product candidates, the protection and market exclusivity provided by Immunic&rsquo;s intellectual property, risks related
to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further
list and descriptions of these risks, uncertainties and other factors can be found in the section captioned &ldquo;Risk Factors,&rdquo;
in the company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025,
and in the company&rsquo;s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings.
Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation
to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic
expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contact Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Immunic, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jessica Breu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President Investor Relations and Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+49 89 2080 477 09</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">jessica.breu@imux.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>US IR Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rx Communications Group</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Paula Schwartz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 917 633 7790</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">immunic@rxir.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>US Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KCSA Strategic Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Caitlin Kasunich</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 212 896 1241</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ckasunich@kcsa.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>imux-20250409.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /KM5s7xRiXgOn8uFZXIsSaaCKcP9wZJ1qelBsG10fQmKfyYqwAEwqyu3ywUGYf0P -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:IMUX="http://imux.com/20250409" elementFormDefault="qualified" targetNamespace="http://imux.com/20250409">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://imux.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="imux-20250409_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="imux-20250409_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>imux-20250409_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>imux-20250409_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://imux.com/role/Cover" xlink:href="imux-20250409.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://imux.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !  /H# 2(  A$! Q$!_\0
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ME\ST)U)T\#*I&IS/H_F>.?M3?LRZG^SCXK@B62;4O"U__P >.I.OS!^\<F.
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M?V [F43RB;_A%U/G"0[\X'.[.<U^54>IW\UNJ2ZC>S1L/F22YD93]03@UYV
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M $![7_P+6C_AW_\ %_\ Z ]K_P"!:T?7<-_S\7WH/KF'_P"?B^\^;Z*^D/\
MAW_\7_\ H#VO_@6M'_#O_P"+_P#T![7_ ,"UH^NX;_GXOO0?7,/_ ,_%]Y\W
MT5](?\.__B__ - >U_\  M:/^'?_ ,7_ /H#VO\ X%K1]=PW_/Q?>@^N8?\
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FB# 4#H *DKX#&8RIC*G//;HNQ\1BL74Q<^>>W1=@HHHKA.(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  09,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUNIC, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">&#160;Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $.+B5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( $.+B5J1.90K[P   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DE%+PS 0Q[^*Y+V]M)L%0]<7Q:<)@@/%MY#<
MMF#3A.2DW;<WC5N'Z ?P,7?__.YW<*WR0KF S\%Y#&0PWDRV'Z)0?L..1%X
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M[4\&VQ.KLN(U?:XLO/07ARO.X!%P-\#G"Z7LVXE[\R]_N.G_"U!+ P04
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !#BXE:1L=-2)4
M  #-    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( $.+B5J1.90K[P   "L"   1              "  <,   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $.+B5J97)PC$ 8  )PG   3
M          "  >$!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M0XN)6O&H^3]U!   Q!$  !@              ("!(@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $.+B5J?H!OPL0(  .(,   -
M          "  <T,  !X;"]S='EL97,N>&UL4$L! A0#%     @ 0XN)6I>*
MNQS     $P(   L              ( !J0\  %]R96QS+RYR96QS4$L! A0#
M%     @ 0XN)6JK$(A8S 0  (@(   \              ( !DA   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( $.+B5HD'INBK0   /@!   :
M      "  ?(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( $.+B5IED'F2&0$  ,\#   3              "  =<2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "$4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="e664373_8k-immunic.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imux.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="e664373_8k-immunic.htm">e664373_8k-immunic.htm</File>
    <File>imux-20250409.xsd</File>
    <File>imux-20250409_lab.xml</File>
    <File>imux-20250409_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e664373_8k-immunic.htm": {
   "nsprefix": "IMUX",
   "nsuri": "http://imux.com/20250409",
   "dts": {
    "inline": {
     "local": [
      "e664373_8k-immunic.htm"
     ]
    },
    "schema": {
     "local": [
      "imux-20250409.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "imux-20250409_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imux-20250409_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://imux.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e664373_8k-immunic.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e664373_8k-immunic.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://imux.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001193805-25-000454-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193805-25-000454-xbrl.zip
M4$L#!!0    ( $.+B5K5><0-?Q<  +)V   6    938V-#,W,U\X:RUI;6UU
M;FEC+FAT;>T]:7?:1M??^17S\C1/[5.S2&S&=G@.QC@E7@-VMB\^@S2 ;"$I
M6@STU[_WSDA"$A*VB9TX;7.:!J29N\W=9R0._C>?ZN2>V8YF&F]_EXKEWPDS
M%%/5C/';W]N#3J_W^_]:N8.)"\-@J.&\S4]<U]HKE6:S67%6*9KVN"0UF\W2
M',?DQ:"]>>HXN5R62I_/3@?*A$UI03,<EQH*"R?IFG&7#1_OAD.'MJ[%AN*5
M $FEM (:[JK+"='!]9*X&1OJI@ZMB:%N,%1SS*HL-=;1(4:$$^998R6D&3AD
MGP_[I\OA;OKXY="2:U/#&9GVE+JPA BI5BC+!;D> 5)PF!(#!-^+8_/^03B[
MA8H4P%E9G#BG>'M(G5#B*DN(.\ )-V"&7 T&>DYA3*D5#AY19\C!^C>2@VU3
M9T[J:'XG-EPQ/<.U%^F$^#=C$QS;704-%V.#>F?7G\-1VM2;%Q5SBB-JY6JY
MF4=S851MY0C^.7 U5V>M@Y+X-W<P92XE.+G OGG:_=M\QS1<9KB%JX4%TE/$
MM[=YE\W=$K>I$LPJ"9 '_U<HD&.-Z>H>&3!WGYS3*=LC<W6^3WI'_,--63ZZ
MN1Z\D8_>M=N7\ ^23@J%1TZN[-X@?S<!7S<!7X\'4>V&DS:876O>,- 1(!S^
M:T^9H<)?]UBGXYL1U1WV!$C="*2N 0NPZ  HF^H]0V7S$[:X*8-'DG?+C4;]
M\6#KAR#>HQOIQC=N 1\N/0&$?#.84)LY-_(-=V4"AL.O/0$,+O31I0^JLD)0
M%NRAJ2Z(XRYT]C8_ GW;(U+9<LF5-H41YVQ&^N:4&COBP@[@M[41JK6JW0?3
M5,VQ=+K8(X9I,+RGS?=019D->L^_:*K*##0"_ :CSKTIP%&$@L_=/AN]S;>=
MBQ%J2*%<+8#E$$U]FS^FBEO&/Y4\,8!IP,6TO9@BY%M<$PY*,<C?@ZL:Q96J
M*OG64E?2$)>B/",9-ALQ&V(I<_A]](][#@]\0 [AT6QO8B-E:&J%P%"*<T?-
M^[==\ AO\XXVM72&7L!'$X,L4#FF9_N88!!?]CV?><YH@GG?-P4C&6<XN!A>
MUE2\,=*833CA+#6&='HG<=DD)X?(2FG8?%P6"-)45TB *&Z[1]1EK27U 9SE
MO>0L4)6,.<&=!$E1[,$U7WPQD7J&)N0)QI44XI11Q[-9RS?"/1@2@ INQ> C
MK'3@PIZSX/O,\S$;(E@ZC202L'!8N!6!XDRN[-0U[>7=)_.>)"\%9@3C$3/,
MJ68\@/-!>221IH -;D?93XK1-[VEI0F3]WW>00GFMG*YW($5N,@IM<>:L4?
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M^#_!?S6Y_SH.SUT,EK6CZ$"(!')E0_07=63X2+:ZO62+/.M3J+^.]HCC!P"
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MN"U][<WL1O>]0NM&:2XUVV?3_D"_>RLD4L*?*^0_@>E.]=;_ U!+ P04
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MQQ\NP:0^/5*_]2\N^J=7P\&E.CM65[\,U.'9F_/^Z;N7\,>O@U/XK?T+-?A
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M(8 #&:,@!1<OHOUYOK/[W3:J=%AGC=XEN873/$5KKV5[W'O AAO\4E+@@*3
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MC1F52>6BC'-LAA/^52+U[%7CZ(CW+#-S4\[UW-X#]#OP##!3V<(@4I5_OH)
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MAWNUP?U$F6DN^#Q] HZ1*YL)^4,4.,)+1C]2NY !LVQ)CJ#M"O@9D8AH.9>
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M@<O_=Q"XO,UNL/D/7(!==?(2[LE=?9S=BU;$W\]>V,[$DP,QW*CDVB&O=O,
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M2NZ'X=Q\A^>?-RV:T!@0PB*)(JB]B+_<,$E#$8R/13<(,MT1@!!HLD'0?[X
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M,HUH>76%-+Y=]QH7(3",Y_?R8S<=&&E0E=E,VUXAOI&$(A%K4&$CE])Y%_Z
M>6R;NIRS5[(@66R;]25/V<N"^G(TR ?V 7/?H?YC?\E&8*GDB5,#W.Y)FDP/
METDI&^%U3:T.S5'!X=#P\4GP],F!ZWNUVQ .8[X80P+&,[#7Y+MY6G]YT)[6
M7_:>UL.6\>FO8VOES!>EH#[Z &8"!5/?.;J06[+1D7ZP;".0L8%*W*<:E1:[
M)#L3U;[P/@AH,Z?J%=MB2Y%DC70(YP[HW#0IM<U1EC,ZY8E0NRGQ9%KA,60Y
M3"C39KJ!"&3'5\8HFN?0A_E<9UDXKQ[U.C&^A?;V?O:FF)X3R?9L($6N<%)X
MK]YV93QDFA*J;KAQ;4.DE'1X)RWEI<@F<R^P?^<G48X5$UHD')A4LLL!9+\-
M#Z[)P6)=@<];B?E3MB8820^6MN'^>ZEH\),3C>W=13 V&J1C3G63O*5+B+Z!
M?RGY!=5!MT3=&OQB?_@]GV[&BN&ERV0%T?]8T#M@8XU1D-PW!CPY,()B[2BJ
MS\!GD.AKR5;9>SI=&Z#/F/J^X02A!+W1A!6X1FY+3\PF:*3-"JJ%0BC9$3'0
M%95'V-B$M5J_8@USPZ:^1!X^;N=.WKO_,/&]T9!:EGN:!'<4)D,A$O>(4Y\+
MORWS$FIKWYG>K8V9Q,&[DP'?HL/7> N>*%X10!1V3=$6A;3Y[?(B8'Y;'"'H
M F_2I8+\97D8IBD"E336:5AMT#H7[;9D7ZI:*EZ_*+ICNZRBYS?;!(AG,MO]
M>RB:7$SZL) .H2#8[I.7H6T+:2_JR'I=V\'Z7JU!B?%#^1<W@VMV;_SI.0?N
MW?T3O^7FG]R,*][]$^6G\]1=L/Q=H56.@PR?Z239WQ059H^W^N,TN* 9%%D@
MW*,5QM=4Q0@&[\X16Z JW!*?O@JC[JQT@</>_7'=66E]I&N$X\6@MK1W]VH%
M_T0#0@)RPGE6)=SXG4CC=0$-URDMU!L=YW>I#H#TP_WRJ+P#+98<K ??)'1.
MZ((@0:VQL\='IQ*YV1_YSZ?_'!_YX <B*O62>U:_16 :R (?_V=@;2UUTV7(
M<)S-(V>GVEK#)6<B;;?DL?69', "I;$Z['3(EN\K??Q7T3-?3W)S^&MQ@]9<
MZE^IDU<,B2W$#NBRJN@&L7%F^@=??4X5<U*%@3_ S;W>!->FL@G#C6G:K&E
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MG1R#7V'<FG9-1LTPVK++2Y^"1.>V+HAXR.O8L%IK6)$/APB>%0FI%G8:MI2
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M2%T^FQ9[_!!8!DJR'$K)8UN D\,U$IKU9L%U&#A#7-_];VQ4PASZS'W?#>(
M2<86M-]IQ/;I1AT9$+[!K!!R8(:&'?'1&_+VC.>: R>XN7&?EMBB*_: ,9PN
M2]#X83?7H!?W+&I;C)#+RZU=LW&N?J(U8@(*"C;PH./\(,)U'-*D($E?76PM
M.!2@*-8D>55%E;Y65[&0#-E9I$"@:<,.U#T7!2$2R,.U8/;*U;H*'#95YX,*
MAG%-G71ZQ;/# U_)!Q<(K)$TH<F2L!SL+3BE2F*W39TG3-2>*0-7.3Z]Q& ]
M#V[A2RBH?8;\IM-^?*,G40"9S^PR9^\?#1I%Z$G 78M [GB<\GC@C]5O]]6C
MUCH963H.-I7Z^!%[_?,J(]3CE ]!R;&GX4 X31TTQ?-':\A$&08V),1)*^JN
MV]<QW]^C/CU^R![UZ?'>HW[8,CZ]NHJDD5^>:9F>"RFNVH88 @V3'RJ+ - D
M"N3GHPL$JTIG^9?M&ASI?%G6GC=NZE&J\BREY;:,@#\R4(MNE?)]\(8OFFY9
M8.Z3V<D<+:#'U)CF$!R Y7L&3WT1/#;Q?>SK->*?$=N;8O9V_I&ZW"55-BLJ
M[J3:$=&T(P AHG<ZM,3#9<\GZH6:JL, P#:E.=8.\CC1J?<L8+SO0"<O04^O
M*=<[.7C'%]E7D,Q9>&4B%^*KL549O&!RG_>+O%[8="_6/&30O\,6+/"BX$HD
MMI,P(K[3>*</SLN3"Q#R2%(30J2/%/0OO#AE'\%?$S>42*UP7-KGF$I/FM:V
M47:5BVERB=+KIXJ,"L52R+<P81@D0&XM_]7D@+Z;5R#ME)3W/](-)!QD*5&R
MH3%',\_."N(>>Z(_2:6A0/*Q*%:*_$?GC[WT5AO.VOZ@6CM44?\&+?,,UB3L
M_WI;8U?3?'55B#-%=RJX_C(=V!W_VQBPB-@$Y=\7-6TBL4('!#JXSN \P5NW
MLU+7D?ND77(;CLPH#062DBSPG%,E"H^+ (\R/J1U8QIX*Q&'R+[!#31WVY+2
MQMD$SW;8QF$[9V$91)F[R5IB:X79HZ(7%P]"@/^Z5@%T-0R@%=USQH#/@CJW
MI0*20&> ,B<=E_/?*?6#G=.8DEWM+"T%-_Q'0'6D'X:; ZN#296P?/(E."+[
MMUC^:>(XB5CP.9J)37P:/4;(^HYJ,O$24+OD+9(:48&-'3\J&3<7L!J@@U W
M=F@VJXQU1?E/BM'Q:-S=>&70%N.?ZQ?<%=#L3U_-[<:=><1JH*G2N]X&L0U+
MKJS.G.J8'%"X4MT/52B!4.]^P*2,ERGJ7QK8 ZJ+2.?U6O/#-4HC87=)U,@]
MZ9:]%+=+(5TW2"AF%&I _R+'OLBTG;!#3U:S5_++NKZ]LR0_>G(0/AL]N&OM
MM$=D-K#.!6?P-R%D2+6-GBI>D6@4]AXJ 3PGW'6@>84MZ$X4_,T.3>B5S\0W
M?O9UBPCZAH^5[6+@:OL^'11H&D>/*-QGT=22!N]BE1>#\_JVLU@& IHJ&I^2
M" </C;F(O$6$ZLT%P? /JAR#U[\J9Z4-'Y-ZQWVF"HR.@37WA"1;,X#V\V*3
M+J&S=E#;F1?7105SF>MIS$P"V^PURR&+@Q2H4*$!")BUELC%4,I) XEB4 ;-
MR<'"W5Z//1T:KY(;D=E H]$.QK7WS'?SS$\>M&=^LO?,'[:,HYDSICL@/N*W
MW!'V794IG>8YN8^V7>PE5A2.==IVELEQL]D;4&UZFRE6C4<.#+;SD/YM"WG
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MLIYX6C,*WH>$+7@C"BQ+YX.GWST^3E9'RZ-D"NL].?COIOV8O"#.*7B5PQ
M"=99RH2U=,S]V@=VVR!0?-]92.PD(!7)[SD+]%IYICD(*:@-7@<K<C)I[I+5
M@XE*8O-4;P8S-3_4$'*# >I3,GKK?$>C%R,Q&>%$<>XP!LMU3S\?71PE;-52
M4J^%VU_65$"'4;^:#%LL?BE1THOV6F8;25ZX.A<T=E8I?9P+/ZH-?'/5+(.5
M*H-6.+1M:%_P(:/+L%#PI>Y<1FX'F];7&=Y_S0;L6Y*6_/ST6W>3Q07L6[ZT
M[C/3;UFBZ%W8MR8'2+_U99THNP3<'A\_Y(#;X^-]P.WAR//3".WK&<)(R8Q\
MEOR=P*,>U#J B\9B480WS5-!F^*_.F>IL[U$.-4B=RT-\&ATY;&FO2CJ9_S]
M,+58\QT<\_4PU&0)YLF6UIQ*CN<Y)C[[Y.GQT<E_4J,,%"&VJDP^"\X<NEY;
MI$CR%%7MO"V9+.U,&%&\E8?$Z:,\*.-OT_#4TY)*.OJ$A]TRIY%^YIF4%FN=
M6"S,;C"DERR%5,'/2PCV;14&C%C0MI'4((-=R0#.<9GQKQ+F$8M*; (7PT^4
M[:$\BI_>0\U3ACT/(L_@NQ9Y[*8A?EH1SX0GGODV0R1^BF5><+.1O%AD2/D2
M[\4ADY9Z]F$FAG$M[2(R/#3'V:#/M)B'T%X\AE*Y(JD!*[.6NN')&KK.6SK0
MR%7:G.7NT2K+ @+H9(YH#BKD$T&OQ76R&,08)??'F 0.0WJ9+94>H*[Q+UBG
MLE4P&__*BB3]FOTF6F+:4RITU*Q6WHZD<BP(WM@9"1Z'2CL?*Y60F8DM#PN4
MA>7GNO#QNR4&OZCF?_L]8J'H1!E9.2%*._76QA[#@5O9%L=2YV5RX'@" DR,
MZ8NLL O0QX82I>3@!=G0 RB[<IJQ($FP:D!)\H799D\C[*-_*\CCZ7R(ZDH^
MT8IY0@JQ.0X>1LG4-35*:MZ0DQ:T?L<]M07<&1 YL/J@""U%0DV/< ,X-9QV
MO+F_N!7[^O=O;7FQGF-XN1&J@K,.S0HG$''M'^P\JORHJ2"7M0S#&/IA4%%V
M7TE>J3R2 ](^0)3QT\,0.QI.% Z@+X>RI7V)6)TU;3QE=W=+(CJ[!UK$4L^"
M?<+E@H=#(B$<GXQ-W<[*\17)N*)4*J,*)31W)@<#I(C,"7&527JA,R'XH:G#
MB3:YL"@42&/B:GQHS\ ZR\>Q5H<DA%]3W$>?HO;9@&=R:\:(@@%:]HW7":.?
M214(C=^7MJG'? !@NL%6:_-'3"CR@^* ,&3A5?,[<'%9<#B[Y+8CK1G^7FP:
MAR-JM['/<.[:$= ,"9@MG//QT8D[.&^_BS[+6 W!?4Y'"F50,"8EUG'UH>%2
MIT4,95\7ZK"1/M'J--0B6ICF'\,F(^UB:QA/#B2O,2ML*RC3VBG1SDZ%RZSZ
M=GU!9M5PZ<@;!$;--U_8P;93F.CD08>)3O9AHH<CST\C5?)_Y=@_G+>OLQM)
MIX&ZAG7N'$1_+E=HE$"S^FER#8_-B;+41C_8U(+% C4<4KMLZ5[LCHA+&HWB
MGW);3DN%5Z+>HOX7-PYOL94BDU]()*B7I(BF7SRZ@0/RGIH:(1FK2LX99=ZC
M&V'O1,D?"P18 T"F;2ZR^<(=*^V20/[)8/K":>G&\Z84@SSZ>Q:@!"S*6TA8
MM2NO,'6Z&%8FKZ29+BY+L(U@,L,XNP/7MJ?8=NS/D3[)IC1>:O$XI%BM.WAH
MM7'U%+2,U!M'^5&)K1A<?CA#I:Z:; .IR]+E#M9+*HA*L!FOFSFQO73KV;+T
MV"'W:-A*;=GEY=S*KQN%DK0B$> NHTB3'QKF0X$/?\KJ*\Q2U>Z4SW+B: UJ
M^C'LLA80FP8F![ 7_(JDGT(V2D-KR4$B[7\I!5YV\W77><8Y0VP0,[4CL<W;
M=O2A-%6.3#<%EH0N2':/E,]@=4/KZNG/'+N=WTULTW 73$7<B[G$Q-P4C^H"
MQOG)P7 =712,5BXU[DCLF63\+3'^)0M K3!AMC30@%4OM<#_V"5RO[6BQV9:
M=#+<X'W6=:%P*J<%%=^FG\\*0M$3HT? ]AI]"?0*.2>,</YYL]HX. PFS$$1
M8@&C "&0FH!B_O0;\E5=?MCAJZ;<K1H].H&?Z5>'#@LC.K(7$>=\KZO2HUH8
ME_6%WY1]W/\<UA$*>RA/E>^A+=&=RZ;)!>.#BHE6:,N\:K-:I]G?-,-*R"$A
MHP\H<T#(L#_XL"R^/RZ,>UAI6;<D1NNM?^[->S0Y>&4COOIBK!-1Z*(KBX%A
MWIRA6W"[WTL1?Z)4"O@E!RC@D;_%RS-JV(!\12Q=#MMXBRR:FL5R.4.N38<&
MI,3Y\&;D<?%9M ,;O8)^AISX'H9IS 5#[1E +A/A<>M,(3ACLV)O]("\HC&B
M?<PC=+&&S02&G_?X[_"WM^RFCNY3!(!PUUO"P#A].N^+*?9Y?/J@G<K3O5/Y
M+R>E.Q:X1&BT%)P>C<4+FD"(/9A9X*9A&JN6J;_1(<H(2"_Q:,[VWRA+8^V!
MQ\958.(J(M*J"Z<WB-4JBR1T9@6<I(5!8]+M[>,-))<1"XX^2LP8<LX4;*FL
M5*:\ TLV>['+!#N,IH@K?-<(88V]5=%FE32!X^)R8SE*7@E6E&@ ?2<5AW0+
M@)\PSD4V)VK (L!.4CX9W^(1&7(!-E[CW$>K?*&MVQFJABC"C/!E0HCA'RLV
M"1)D81J-O'^:&,VT>./!QD7!^)42!K@$ 0/<OX@X8HDE9O"8LG,"<^B/:YHE
MM7046$NTHG(#/PGPB,CKN0=@01)LTQNDY:<N[.4E=LIP'O[#.<]WW-7CVIP+
MXGYAWD_>V&*<8FU4&@(=I+R=< [,0A%'%I48':\XMB.MAKC\=U40S[UUU"CG
M2CAK$C*P5"N*K:3)=5/FW*-%[%XT"%.)^R-9B^E^0TPL9K0!A3TW.'(#MLA2
M:Z=@KQGJ[PK_OUB#^(]%T&F9$NO?E I. 06IP#'8N9(7RAQ)<21Y$/3#+!GO
MC"@.=&]- ^G"LBLOREJ"9-R4 N%5%87#2-UA%S"I%;_"GM-^1Y';.L,ZAY[Q
M'.X;Z<24B=LU"#Y) G!7>0 !$@D@+QCD<;7F6[%B1<Y A]312%D]U"2E^H#P
M 7A=S;K*I0F/.V&\()![="\)T,!@R/*H6!&A5:#%Q==@X+H.'3%O_W][5]O4
M-I*$OU/%?U!QMU=0Y84 2:Z6R[I6V )T,9)+DD-26U=7PI8356S+)\OAV%^_
MT]WS*ME@%CL!X_V0-;9>1J.9GNZ>IY]GH;'Z\LQ+M?8H2"9=#G."EW#%^KV7
MQS?,!@<000N@8DDH3Q 5E<K\3.*B7;W>%8-T\1XY>:Z&Q(,@>4_/9MV1.:VA
MRX#ULB9Z22"L4+PL150?$@'S>KUA3&R>&<$-*82.]7ML;TET>5F-J)>)_!AG
M-J:*/YZ:I?FC PDTW3\B../%6.P[R4.,H7^9YP'5K')X*]3:&_Y&,$4 =YN
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M8,+GM#G>9.J6VVZM6V]GCP8[/AD>X=OAL?WC#T=G@\/@_)A>] Y6 ._L#-_
M//[GP^!,']\ 'GU_TC_ZM=O#5?1Q0N_AH?[9\1%LX*^PS_N#DW/:R_-CIA/Y
M!FS)N_ZYNS"@!MQ''&1HCNZL/SS@ \,YP'Y].#H<G)W1QN)G@\/AVR&/@$=
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M]!A,:A(EH*0B)\X<K@U+"H/),EGA*L=+7,+)P1M0%1<KU$! H91518_G(8B
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MP IZZM1]#0'8PSPDS=%Q1?LLE[0C'Q2%\51Z:KJ6N=:PD&]K>MUB63[7DMH
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M*BP53Z 7P <"J?+O7#%6!8M<:J]V3?P:ASN:Z88RG5(7I*A? &&W%M1XA=B
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M.6 X@ZC:KLA#C[0\.C0Q[$UI&,BZ)!X,/VPJML7*5>AB< 3]AI<12Q2-65E
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MW?(TBV2V#MPOID_5Z'00L-\:4;-(^OY#3?B-8-(7]QDF??$ D]YO"A_56 /
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MU4X.!N8X<$OE*03)971D'I$7D"/>Z:8XA6I-5CHF.N;BODOM0'5'"]1RBMT
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MB!&T:$OC.P0[R63P*9WE-+K 8D=57SFVZ8SPI3O;:*W!S86O3[#&B@.Z6#F
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M(?<&XD303@=F-6,J-OJIYI>QB:*SGTNNN17EHFL(!B\(DG ( A+K]HC1?]9
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M%B%"A6EVE8<+/0@"W$<BXX><?YI>! .,:KTU7/K.0=M'#S1QVS3Q>KAK0@.
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MAC#\M'=\\"OMSKOS]X>[_Q]02P,$%     @ 0XN)6A#PHT,A"0  5B4  !$
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M2IY'Q2[]793]0RGZ>ZI_ U!+ P04    " !#BXE:1STK/[@.   J,@  $@
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M[64AWDKK<5 G?K.F*@F(4SW3+IK888[U$DP[ GIZF74[]?P>V;,,GB!=L$_
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M7.;P7E ;V5"/N46W(].0LD%K8(JZ?]W,Z.E,4R[2B(18"("OKPEZGNJ1#A0
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M#0XQF>YV(GP$19-S<A@,*)8R+0BI,>7$</<OJF1 "0:NPW)^B\.#3/..<+)
M*XCA <:)L,))KB*/^ADB2K/^W_I]\4RK+'T$TCI1^UCD4Z6*1&&O??&FY%+
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M$'9OW?MF_/S-F2'R1=PXMO\CN/473[/X\FL\6T2-13RZ>?+M^S1D6[@O*(!
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MVA)7;$#F-!-F>1 L *9,!@H94CI4"+WTO+Y+P#+U$"/8'%/FE@"[R28%34U
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MLQ<  &4V-C0S-S-?97@Q,"TQ+FAT;5!+ 0(4 Q0    ( $.+B5HLQB0V+8,
M +C0 @ 2              "  99"  !E-C8T,S<S7V5X,3 M,BYH=&U02P$"
M% ,4    " !#BXE:MYYJ?<)'   1A@$ $0              @ 'SQ0  938V
M-#,W,U]E>#0M,2YH=&U02P$"% ,4    " !#BXE:$/"C0R$)  !6)0  $0
M            @ 'D#0$ 938V-#,W,U]E>#4M,2YH=&U02P$"% ,4    " !#
MBXE:1STK/[@.   J,@  $@              @ $T%P$ 938V-#,W,U]E>#DY
M+3$N:'1M4$L! A0#%     @ 0XN)6LOE$6,F P  U@L  !$
M ( !'"8! &EM=7@M,C R-3 T,#DN>'-D4$L! A0#%     @ 0XN)6N6(/RW]
M"@  ?X8  !4              ( !<2D! &EM=7@M,C R-3 T,#E?;&%B+GAM
M;%!+ 0(4 Q0    ( $.+B5I/Z]Z+4P<  ,Q7   5              "  :$T
M 0!I;75X+3(P,C4P-# Y7W!R92YX;6Q02P4&      D "0!' @  )SP!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>e664373_8k-immunic_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imux-20250409.xsd" xlink:type="simple"/>
    <context id="AsOf2025-04-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2025-04-09</startDate>
            <endDate>2025-04-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-04-09" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-04-09" id="Fact000004">0001280776</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-04-09" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-04-09" id="Fact000010">2025-04-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-04-09" id="Fact000011">IMMUNIC, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-04-09" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-04-09" id="Fact000013">001-36201</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-04-09" id="Fact000014">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-04-09" id="Fact000015">1200 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-04-09" id="Fact000016">&#160;Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-04-09" id="Fact000017">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-04-09" id="Fact000018">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-04-09" id="Fact000019">10036</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="AsOf2025-04-09" id="Fact000020">US</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="AsOf2025-04-09" id="Fact000021">(332)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-04-09" id="Fact000022">255-9818</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-04-09" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-04-09" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-04-09" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-04-09" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-04-09" id="Fact000027">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-04-09" id="Fact000028">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-04-09" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-04-09" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
